Search
Ciglitazone
go.drugbank.com/drugs/DB09201ExperimentalDeveloped by Takeda Pharmaceuticals in the early 1980s, it is considered the prototypical compound for the thiazolidinedione class. … Several analogues were later developed, some of which—such as pioglitazone and troglitazone—made it to the market.
KC706
go.drugbank.com/drugs/DB05157InvestigationalKC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. … KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.
9-(4-hydroxybutyl)-N2-phenylguanine
go.drugbank.com/drugs/DB02495ExperimentalThis compound belongs to the hypoxanthines. These are compounds containing the purine derivative 1H-purin-6(9H)-one. 9-(4-hydroxybutyl)-n2-phenylguanine is known to target thymidine kinase.
Laropiprant
go.drugbank.com/drugs/DB11629ApprovedWithdrawnLaropiprant is an ingredient in the EMA-withdrawn product Pelzont.
Biguanide
go.drugbank.com/drugs/DB13100ApprovedInvestigationalWithdrawnBiguanide has been investigated for the treatment of Diabetes Mellitus.
Alizapride
go.drugbank.com/drugs/DB01425InvestigationalThis kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, including that which may occur postoperatively.
Categories: Dopamine D2 Receptor AntagonistsSafflower oil
go.drugbank.com/drugs/DB09446ApprovedInvestigationalWithdrawnacid [A32677, A32679], depending on the flower type. … Safflower (_Carthamus tinctorius_ L) is a herbaceous plant in the Asteraceae family.
Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA top...
Ganulameran
go.drugbank.com/drugs/DB16442InvestigationalThe BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to [BNT162b2], BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. … Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it.
Piclamilast
go.drugbank.com/drugs/DB01791ExperimentalIt has been investigated for its applications to the treatment of conditions such as chronic obstructive pulmonary disease, bronchopulmonary dysplasia and asthma. … The structure for piclamilast was first elucidated in a 1995 European patent application and exhibits the structural functionalities of cilomilast and roflumilast.